2-甲基苯并噻唑-5-羧酸 | 24851-69-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-甲基苯并噻唑-5-羧酸
• 中文别名: 2-甲基-苯并噻唑-5-羧酸
• 英文名称: 2-methylbenzo[d]thiazole-5-carboxylic acid
• 英文别名: 2-methyl-1,3-benzothiazole-5-carboxylic acid
• CAS: 24851-69-2
• 化学式: C₉H₇NO₂S
• mdl: MFCD00498510
• 分子量: 193.226
• InChiKey: TVUFPZOJUJGDDD-UHFFFAOYSA-N

物化性质

• 熔点：
  202 °C
• 沸点：
  385.2±15.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  2-甲基苯并噻唑-5-羧酸 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-Formyl-1,3-benzothiazole-5-carboxylic acid
  参考文献：
  名称：

  Potent and orally efficacious benzothiazole amides as TRPV1 antagonists

  摘要：

  Benzothiazole amides were identified as TRPV1 antagonists from high throughput screening using recombinant human TRPV1 receptor and structure-activity relationships were explored to pinpoint key pharmacophore interactions. By increasing aqueous solubility, through the attachment of polar groups to the benzothiazole core, and enhancing metabolic stability, by blocking metabolic sites, the drug-like properties and pharmokinetic profiles of benzothiazole compounds were sufficiently optimized such that their therapeutic potential could be verified in rat pharmacological models of pain. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.018
• 作为产物：
  描述：

  甲基2-甲基-1,3-苯并噻唑-5-羧酸酯 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 2-甲基苯并噻唑-5-羧酸
  参考文献：
  名称：

  Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype

  摘要：

  This Letter details our efforts to discover structurally unique M-4 PAMs containing 5,6-heteroaryl ring systems. In an attempt to improve the DMPK profiles of the 2,3-dimethyl-2H-indazole-5-carboxamide and 1-methyl-1H-benzo[d][1,2,3]triazole-6-carboxamide cores, we investigated a plethora of core replacements. This exercise identified a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide core that provided improved M-4 PAM activity and CNS penetration.

  DOI：

  10.1016/j.bmcl.2019.126812

文献信息

• [EN] HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE FXR (NR1H4) CONTENANT DES GROUHYDROXY
  申请人：GILEAD SCIENCES INC

  公开号：WO2016096115A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds (1) which bind to the NR1 H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds (1) for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及结合NR1 H4受体（FXR）并作为FXR激动剂的化合物（1）。本发明还涉及利用这些化合物（1）制备药物以治疗疾病和/或病况，通过这些化合物结合所述核受体，并涉及这些化合物的合成过程。
• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。
• Carboxylation of Aromatic and Aliphatic Bromides and Triflates with CO₂ by Dual Visible-Light-Nickel Catalysis
  作者：Qing-Yuan Meng、Shun Wang、Burkhard König

  DOI：10.1002/anie.201706724

  日期：2017.10.16

  We report the efficient carboxylation of bromides and triflates with K2CO3 as the source of CO2 in the presence of an organic photocatalyst in combination with a nickel complex under visible light irradiation at room temperature. The reaction is compatible with a variety of functional groups and has been successfully applied to the synthesis and derivatization of biologically active molecules. In particular

  我们报告了在室温下可见光照射下，在有机光催化剂与镍配合物的存在下，使用K 2 CO 3作为CO 2的源，溴化物和三氟甲磺酸酯的有效羧化反应。该反应与多种官能团相容，并已成功地应用于生物活性分子的合成和衍生化。特别地，未活化的环状烷基溴化物的羧化反应按照我们的方案进行得很好，从而扩展了这种转化的范围。光谱和光谱电化学研究表明Ni 0物种作为催化反应性中间体的产生。
• [EN] GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE GLYCOSIDASES
  申请人：ASCENEURON SA

  公开号：WO2016030443A1

  公开（公告）日：2016-03-03

  Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式（I）中A、R、W、Q、n和m的含义如权利要求所述，可用于治疗tau病和阿尔茨海默病。
• [EN] THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS THIAZOLIDINES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010004507A1

  公开（公告）日：2010-01-14

  The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially as orexin receptor antagonists.

  这项发明涉及式(I)的噻唑啉衍生物，其中A、B和R1如描述中所述，以及这些化合物的盐，特别是药学上可接受的盐，以及它们作为药物的用途，特别是作为促进睡眠的药物受体拮抗剂。

表征谱图